← Leaderboards
Andre Larochelle
National Heart, Lung, And Blood Institute
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsHematopoietic Stem CellsCd34 GeneGenesTransplantationEngraftmentStem CellsInheritedHematopoiesisMutationGene TherapyIn VitroHematological DiseasePathway InteractionsMediatingSignal TransductionBaseIn VivoHematopoieticBone Marrow Failure SyndromeMolecularProgenitorAffectGenetic
Grant awards (41)
Gene Therapy for Inherited Blood Disorders$1,439,551
ZIA · FY2025 · HL · contact PI
Generation of Hematopoietic Stem and Progenitor Cells from iPSCs$1,079,663
ZIA · FY2025 · HL · contact PI
Eltrombopag for the Treatment of Fanconi Anemia$1,079,663
ZIA · FY2025 · HL · contact PI
Gene Therapy for Inherited Blood Disorders$1,497,052
ZIA · FY2024 · HL · contact PI
Generation of Hematopoietic Stem and Progenitor Cells from Human iPSCs$1,122,789
ZIA · FY2024 · HL · contact PI
Eltrombopag for the Treatment of Fanconi Anemia$1,122,789
ZIA · FY2024 · HL · contact PI
Gene Therapy for Inherited Blood Disorders$1,332,597
ZIA · FY2023 · HL · contact PI
Generation of Hematopoietic Stem and Progenitor Cells from Human iPSCs$1,332,597
ZIA · FY2023 · HL · contact PI
Eltrombopag for the Treatment of Bone Marrow Failure Syndromes$666,298
ZIA · FY2023 · HL · contact PI
Gene Therapy for Inherited Blood Disorders$1,183,964
ZIA · FY2022 · HL · contact PI
Generation of Hematopoietic Stem and Progenitor Cells from Human iPSCs$927,414
ZIA · FY2022 · HL · contact PI
Eltrombopag for the Treatment of Bone Marrow Failure Syndromes$618,276
ZIA · FY2022 · HL · contact PI
Hematopoietic Stem and Progenitor Cell Expansion$309,138
ZIA · FY2022 · HL · contact PI
Gene Therapy for Inherited Blood Disorders$1,165,731
ZIA · FY2021 · HL · contact PI
Generation of Hematopoietic Stem and Progenitor Cells from Human iPSCs$874,298
ZIA · FY2021 · HL · contact PI
Eltrombopag for the Treatment of Bone Marrow Failure Syndromes$582,866
ZIA · FY2021 · HL · contact PI
Hematopoietic Stem and Progenitor Cell Expansion$291,433
ZIA · FY2021 · HL · contact PI
Gene Therapy for Inherited Blood Disorders$821,757
ZIA · FY2020 · HL · contact PI
Generation of Hematopoietic Stem and Progenitor Cells from Human iPSCs$821,757
ZIA · FY2020 · HL · contact PI
Hematopoietic Stem and Progenitor Cell Expansion$547,838
ZIA · FY2020 · HL · contact PI
Eltrombopag for the Treatment of Bone Marrow Failure Syndromes$547,838
ZIA · FY2020 · HL · contact PI
Generation of Hematopoietic Stem and Progenitor Cells from Human iPSCs$677,161
ZIA · FY2019 · HL · contact PI
Eltrombopag for the Treatment of Bone Marrow Failure Syndromes$677,161
ZIA · FY2019 · HL · contact PI
Hematopoietic Stem and Progenitor Cell Expansion$462,152
ZIA · FY2019 · HL · contact PI
Gene Therapy for Inherited Blood Disorders$462,152
ZIA · FY2019 · HL · contact PI
Regenerative Therapies for Inherited Blood Disorders-iPSC differentiation$581,496
ZIA · FY2018 · HL · contact PI
Regenerative Therapies for Inherited Blood Disorders-HSC expansion$480,358
ZIA · FY2018 · HL · contact PI
Regenerative Therapies for Inherited Blood Disorders-Gene therapy$480,358
ZIA · FY2018 · HL · contact PI
Investigation of the mechanisms of action of eltrombopag$379,220
ZIA · FY2018 · HL · contact PI
Regenerative Therapies for Inherited Blood Disorders-iPSC differentiation$524,511
ZIA · FY2017 · HL · contact PI
Regenerative Therapies for Inherited Blood Disorders-HSC expansion$524,511
ZIA · FY2017 · HL · contact PI
Investigation of the mechanisms of action of eltrombopag$339,113
ZIA · FY2017 · HL · contact PI
Regenerative Therapies for Inherited Blood Disorders-Gene therapy$339,113
ZIA · FY2017 · HL · contact PI
Regenerative Therapies for Inherited Blood Disorders-HSC expansion$587,214
ZIA · FY2016 · HL · contact PI
Regenerative Therapies for Inherited Blood Disorders-iPSC differentiation$587,214
ZIA · FY2016 · HL · contact PI
Regenerative Therapies for Inherited Blood Disorders-Gene therapy$391,476
ZIA · FY2016 · HL · contact PI
Investigation of the mechanisms of action of eltrombopag$391,476
ZIA · FY2016 · HL · contact PI
Regenerative Therapies for Inherited Blood Disorders$1,663,969
ZIA · FY2015 · HL · contact PI
Investigation of the mechanisms of action of eltrombopag$415,992
ZIA · FY2015 · HL · contact PI
Hematopoietic stem cell (HSC) genetic and cellular therapies$1,416,882
ZIA · FY2014 · HL · contact PI
Hematopoietic stem cell (HSC) development, self-renewal and differentiation$826,811
ZIA · FY2013 · HL · contact PI